Sun Pharmaceutical Industries Ltd. has outlined its strategic outlook, focusing on both domestic and international markets. The company sees significant commercial potential for Semaglutide, a widely used diabetes and weight-loss drug, and is preparing for a Day-1 launch in India upon patent expiry, though it anticipates a highly competitive landscape. Management noted that its specialty portfolio is currently concentrated in developed markets, especially the U.S., where price gaps compared to other global regions persist and may affect future planning. As global regulatory and geopolitical dynamics continue to shift, Sun Pharma will monitor the impact on its specialty business and adapt its strategy accordingly.